Author’s Reply to Srinivas: “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection”

Detalles Bibliográficos
Autor principal: Namour, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661215/
https://www.ncbi.nlm.nih.gov/pubmed/26482170
http://dx.doi.org/10.1007/s40262-015-0336-5
_version_ 1782402941302341632
author Namour, Florence
author_facet Namour, Florence
author_sort Namour, Florence
collection PubMed
description
format Online
Article
Text
id pubmed-4661215
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-46612152015-12-04 Author’s Reply to Srinivas: “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection” Namour, Florence Clin Pharmacokinet Commentary Springer International Publishing 2015-10-20 2015 /pmc/articles/PMC4661215/ /pubmed/26482170 http://dx.doi.org/10.1007/s40262-015-0336-5 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Commentary
Namour, Florence
Author’s Reply to Srinivas: “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection”
title Author’s Reply to Srinivas: “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection”
title_full Author’s Reply to Srinivas: “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection”
title_fullStr Author’s Reply to Srinivas: “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection”
title_full_unstemmed Author’s Reply to Srinivas: “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection”
title_short Author’s Reply to Srinivas: “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection”
title_sort author’s reply to srinivas: “pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (glpg0634), a selective jak1 inhibitor, in support of phase iib dose selection”
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661215/
https://www.ncbi.nlm.nih.gov/pubmed/26482170
http://dx.doi.org/10.1007/s40262-015-0336-5
work_keys_str_mv AT namourflorence authorsreplytosrinivaspharmacokineticsandpharmacokineticpharmacodynamicmodelingoffilgotinibglpg0634aselectivejak1inhibitorinsupportofphaseiibdoseselection

Ejemplares similares